Egile-bilaketaren emaitzak

1

Chronic Lung Disease after Premature Birth nork Vivek Subbiah

Argitaratua 2008

Testu osoa
Carta

Gogokoenen artean sartu

Gorde:
2

The next generation of evidence-based medicine nork Vivek Subbiah

Argitaratua 2023

Testu osoa Testu osoa
Revisão

Gogokoenen artean sartu

Gorde:
3

Tissue-agnostic cancer therapies: promise, reality, and the path forward nork Vivek Subbiah

Argitaratua 2025

Testu osoa
Artigo

Gogokoenen artean sartu

Gorde:
4

Challenging Standard-of-Care Paradigms in the Precision Oncology Era nork Vivek Subbiah, Razelle Kurzrock

Argitaratua 2018

Testu osoa Testu osoa
Revisão

Gogokoenen artean sartu

Gorde:
5

Managing Cancer Care during the COVID-19 Pandemic and Beyond nork Omar Alhalabi, Vivek Subbiah

Argitaratua 2020

Testu osoa Testu osoa
Artigo

Gogokoenen artean sartu

Gorde:
6

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis nork Vivek Subbiah, Razelle Kurzrock

Argitaratua 2023

Testu osoa
Artigo

Gogokoenen artean sartu

Gorde:
7

Tumor-agnostic drug development in dMMR/MSI-H solid tumors nork Deepak Bhamidipati, Vivek Subbiah

Argitaratua 2023

Testu osoa Testu osoa
Revisão

Gogokoenen artean sartu

Gorde:
8

Clinical development and management of adverse events associated with FGFR inhibitors nork Vivek Subbiah, Srđan Verstovšek

Argitaratua 2023

Testu osoa Testu osoa
Revisão

Gogokoenen artean sartu

Gorde:
9

Advances in Targeting RET-Dependent Cancers nork Vivek Subbiah, Gilbert J. Cote

Argitaratua 2020

Testu osoa
Revisão

Gogokoenen artean sartu

Gorde:
10

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy nork Mohamed A. Gouda, Vivek Subbiah

Argitaratua 2023

Testu osoa
Revisão

Gogokoenen artean sartu

Gorde:
11

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors nork Mohamed A. Gouda, Vivek Subbiah

Argitaratua 2023

Testu osoa Testu osoa
Revisão

Gogokoenen artean sartu

Gorde:
12

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers nork Mohamed A. Gouda, Vivek Subbiah

Argitaratua 2023

Testu osoa Testu osoa
Revisão

Gogokoenen artean sartu

Gorde:
13

Clinical Development of BRAF plus MEK Inhibitor Combinations nork Vivek Subbiah, Christina S. Baik, John M. Kirkwood

Argitaratua 2020

Testu osoa Testu osoa
Revisão

Gogokoenen artean sartu

Gorde:
14

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm nork Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Argitaratua 2020

Testu osoa Testu osoa
Revisão

Gogokoenen artean sartu

Gorde:
15

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives nork Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

Argitaratua 2017

Testu osoa Testu osoa
Artigo

Gogokoenen artean sartu

Gorde:
16

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians nork Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

Argitaratua 2020

Testu osoa
Editorial

Gogokoenen artean sartu

Gorde:
17

State-of-the-Art Strategies for Targeting RET-Dependent Cancers nork Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

Argitaratua 2020

Testu osoa
Revisão

Gogokoenen artean sartu

Gorde:
18

The abscopal effect in patients with cancer receiving immunotherapy nork Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

Argitaratua 2023

Testu osoa Testu osoa
Revisão

Gogokoenen artean sartu

Gorde:
19

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? nork Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

Argitaratua 2025

Testu osoa
Revisão

Gogokoenen artean sartu

Gorde:
20

The emerging role of PI3K inhibitors for solid tumour treatment and beyond nork Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Argitaratua 2023

Testu osoa
Revisão

Gogokoenen artean sartu

Gorde:

Chronic Lung Disease after Premature Birth nork Vivek Subbiah

The next generation of evidence-based medicine nork Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward nork Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era nork Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond nork Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> nork Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors nork Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors nork Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers nork Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy nork Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors nork Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers nork Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations nork Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm nork Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives nork Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians nork Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers nork Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy nork Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? nork Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond nork Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Bilaketaren emaitzak - Vivek Subbiah

Chronic Lung Disease after Premature Birth nork Vivek Subbiah

The next generation of evidence-based medicine nork Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward nork Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era nork Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond nork Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> nork Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors nork Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors nork Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers nork Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy nork Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors nork Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers nork Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations nork Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm nork Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives nork Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians nork Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers nork Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy nork Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? nork Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond nork Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Bilaketa egiteko lanabesak:

Antzeko gaiak